Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma
Latest Information Update: 24 Jan 2024
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SYMPATICO
- Sponsors Pharmacyclics
- 12 Dec 2023 Primary endpoint has been met. (progression-free survival (PFS) by investigator (INV) assessment using Lugano criteria), as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 26 Sep 2023 Planned End Date changed from 29 Sep 2023 to 15 Nov 2024.